Date | Capital Expenditure | Free Cash Flow | Depreciation And Amortization | Deferred Income Tax |
---|
CEO | Mr. Richard Lowenthal M.B.A., M.S., MSMSEL |
IPO Date | Dec. 4, 2020 |
Location | United States |
Headquarters | 3525 Del Mar Heights Road |
Employees | 24 |
Sector | Healthcare |
Industries |
ARS Pharmaceuticals, Inc. develops ARS-1, a novel intranasal epinephrine spray with absorption technology for patients and their families at-risk of severe allergic reactions to food, medications, and insect bites. Its product includes Neffy, a low-dose intranasal epinephrine nasal spray. The company was incorporated in 2015 and is based in San Diego, California.
Past 5 years
USD 1.36
USD 11.57
USD 1.88
USD 1.23
USD 1.45
USD 3.84
USD 1.94
USD 2.57
StockViz Staff
February 3, 2025
Any question? Send us an email